Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
BörsenkürzelNAUT
Name des UnternehmensNautilus Biotechnology Inc
IPO-datumAug 07, 2020
CEOMr. Sujal Patel
Anzahl der mitarbeiter155
WertpapierartOrdinary Share
GeschäftsjahresendeAug 07
Addresse2701 Eastlake Ave East
StadtSEATTLE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl98102
Telefon12063332001
Websitehttps://www.nautilus.bio/
BörsenkürzelNAUT
IPO-datumAug 07, 2020
CEOMr. Sujal Patel
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten